Brand name authorized in: Brazil Hong Kong Lithuania Poland Singapore
The drug AFRIN contains one active pharmaceutical ingredient (API):
Oximetazoline is an imidazoline derivative. It exhibits sympathomimetic activity and specifically stimulates the α-adrenergic receptors of the sympathetic system. When administered topically to the nose it causes vasoconstriction of the expansed arterioles of the mucosal nose and a concurrent reduction in blood flow. It also reduces the hypersecretion of the nasal mucosa, ultimately contributing to the decongestion of the nasal mucosa.
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
This drug has been assigned below unique identifiers within the countries it is being marketed: